Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Locally produced HTK-like solution versus Custodiol HTK in liver transplantation
IRCT20200106046029N1Phase 3Completed
- Sponsor
- Pharmed Cina Caspian Pouyesh
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of Custodiol HTK Solution in hepatic disease (2 arms), sponsored by Pharmed Cina Caspian Pouyesh. Primary endpoints: Primary non-function of liver, AST changes after transplantation and 4 more. Started Apr 2019; status: completed.
02
Drugs
Custodiol HTK Solution
03
Conditions
hepatic disease
Beyond the preview
Go deeper on IRCT20200106046029N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200106046029N1.